Articles from Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system, first approved in 2021—today announced the enrollment of initial patients in the NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study.

GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and accelerated computing to enhance Hyperfine portable imaging technology—making brain MRI faster, smarter, and more affordable on a global scale.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 4,511,278 shares of the Company’s Class A common stock and warrants to purchase up to 4,511,278 shares of Class A common stock. Each share of Class A common stock and accompanying warrant were sold together at a combined offering price of $1.33 in a registered direct offering. The warrants have an exercise price of $1.33 per share, are immediately exercisable and will expire five years from the initial exercise date. All of the securities in the offering are being sold by Hyperfine.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of two studies at the 2025 International Stroke Conference (ISC), which provide evidence supporting the value of AI-powered portable MRI in acute ischemic stroke triage and diagnosis. Notably, this includes patient data in the Acute Ischemic Stroke Detection with Portable MR (ACTION PMR) study.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced further global expansion of its commercial operations through agreements with experienced distributors to support commercial expansion plans of the Swoop® system into Turkey, Israel, and Saudi Arabia. These distribution agreements strengthen the company’s global expansion strategy, broadening access to MR brain imaging in regions with large populations, low penetration of MRI, and significant unmet healthcare needs.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today highlighted data and conclusions presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. Contributions from eleven leading institutions—early adopters of point-of-care MR brain imaging technology—underscore the increasing utility of AI-powered portable MR imaging and the growing physician experience with its application, particularly for acute stroke diagnosis.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster the capability of Hyperfine to drive Swoop® system commercial adoption in hospital inpatient and outpatient settings and expand to neurology office settings.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the issuance of new MRI standards by the Intersocietal Accreditation Commission (IAC), a leading CMS-approved accrediting body. The new standards, effective immediately, now include portable MR scanning at the point of care.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that ten scientific abstracts highlighting ultra-low-field imaging will be presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. For Hyperfine, this marks the largest number of presentations at RSNA to date, underscoring the growing interest in and expanding applications of the Swoop® system across varied professional healthcare environments.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming BTIG Digital Health Forum on Monday, November 25, 2024. Management will also participate in the Mizuho Healthcare Conference in New York, NY, on Wednesday, December 11, 2024.

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced CE approval of its latest generation of AI-powered Swoop® system software under the European Medical Device Regulation (MDR, EU No. 2017/745). This approval marks a significant step in positioning Hyperfine for broad European launch of the Swoop® Portable MR Imaging® system, enabling faster, high-quality MR brain imaging that supports critical diagnostic decisions across diverse healthcare settings.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of additional research data and images using the Swoop® system to image patients with Alzheimer’s disease who are part of the observational, investigator-initiated CARE PMR study.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today congratulates investigators at Johns Hopkins Hospital and the University of Texas-Houston on the publication of an exciting study using the Swoop® system for patients on extracorporeal membrane oxygenation (ECMO) support.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of interim data supporting the role portable ultra-low-field MRI can play in acute stroke workup in a hospital emergency department setting.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a collaboration with the Medical University of South Carolina to assess the brains of astronauts before and after embarking on the Polaris Dawn mission.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. Members of management are scheduled to present on Monday, September 9, 2024, at 7:00 am ET. Management will also be hosting in-person meetings at the 2024 Wells Fargo Healthcare Conference in Boston, MA on Thursday, September 5th, 2024.

─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin─ Raises FY 2024 Revenue Guidance to $13-16M

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of data using the Swoop system to image patients with Alzheimer’s disease including initial data from the CARE PMR study. The data was presented at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia from July 28 to August 1.

Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced the clearance of the ninth generation of AI-powered Swoop® system software. This advanced software significantly reduces scan times across multiple MR sequences without sacrificing image quality. The U.S. Food and Drug Administration (FDA) clearance of this software further solidifies Hyperfine as a leader in AI-powered health technology.

Hyperfine (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today highlights the results from a multi-site observational study that showed the value of using Swoop® system images to quickly assess stroke patients and help guide physicians making critical treatment decisions. This publication marks the first to include a subset of ACTION PMR study data and shows encouraging results.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that two presentations on the clinical utility of portable ultra-low-field MRI for Alzheimer's disease monitoring have been accepted in the developing topics poster sessions at the upcoming 2024 Alzheimer’s Association International Conference, July 28–August 1 in Philadelphia.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it will host an analyst and investor education webcast at 2:00 PM Eastern Time on Tuesday, June 25, 2024, focusing on clinical developments in ultra-low-field (ULF) MR imaging.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming Jefferies Global Healthcare Conference, in New York, NY. Members of management are scheduled to present on Thursday, June 6, 2024, at 3:00 pm ET.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that the company participated in the American Society of Neuroradiology (ASNR) 2024 Annual Meeting held in Las Vegas between May 18–22, 2024. This event featured several sessions showcasing the unique capabilities of the Swoop® Portable MR Imaging® system. There was significant additional focus on the importance of MRI in the care of Alzheimer’s patients—an area of great opportunity for portable MR imaging.

GUILFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with three experienced and accomplished distributors to support commercial expansion plans of the Swoop® system into European markets with an initial focus on France, the United Kingdom, and Italy.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the acceptance of seventeen ultra-low-field MRI-related abstracts that will be presented at the 2024 International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting, being held from May 4–9 in Singapore. These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that the first patients have been enrolled in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study. The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).

GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2023 financial results and provided a business update.

Hyperfine, Inc. (Nasdaq: HYPR), the developer of the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced an exclusive demonstration of the Swoop® system and UNITY (Ultra low-field Neuroimaging In The Young) project to The Princess Royal at the Centre for Neuroimaging Sciences, King’s College London.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced plans to present at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference, taking place virtually. Members of management are scheduled to present on Wednesday, March 13, 2024, at 2:40 pm ET.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system–the Swoop® system, and Athletic Heart Cardiac and Metabolic Testing, LLC (Athletic Heart), a mobile medical diagnostic company providing streamlined, comprehensive testing for collegiate, professional, and former professional athletes, today announced a collaboration to bring portable brain imaging screenings to current and retired professional athletes, starting with retired professional basketball players.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that four abstracts highlighting ultra-low-field imaging data will be presented at the 2024 International Stroke Conference (ISC), held from February 7–9 in Phoenix. These abstracts demonstrate the depth and breadth of research into the clinical utility and applications of portable ultra-low-field MR imaging.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced the launch of the AI-powered eighth generation of Swoop® system software. The software’s diffusion-weighted imaging (DWI) AI denoising feature received U.S. Food and Drug Administration (FDA) clearance in October 2023, and it has been rolled out at select sites over the past several weeks through a limited market release. The latest software improves Swoop® system image quality and introduces valuable ease-of-use features, including a real-time aid for more precise patient loading and positioning and a streamlined image upload process.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America (RSNA) 2023 Annual Meeting in Chicago. These studies analyzed how portable MR brain imaging may assist physicians in the diagnosis and management of neurological conditions in critical care settings.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced plans to present at the upcoming Piper Sandler 35th Annual Healthcare Conference, in New York. Members of management are scheduled to present on Thursday, November 30, 2023, at 9:30 am PT.

GUILFORD, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced third quarter 2023 financial results and provided a business update.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced initial findings from the multicenter observational study Assessing Brain Injury Using Portable Magnetic Resonance Imaging in Patients With Extracorporeal Membrane Oxygenation.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced the promotions of neuroradiologists, Dr. Edmond Knopp and Dr. Chip Truwit. Effective immediately, Drs. Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced FDA clearance of updated software. Built on a robust AI foundation, the latest software brings image quality enhancements to the Swoop® system’s diffusion-weighted imaging (DWI) sequence.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually. Members of management are scheduled to present on Thursday, September 21, 2023, at 1:00 pm ET.

GUILFORD, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, point-of-care MRI system, today announced second quarter 2023 financial results and provided a business update.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the second quarter 2023 on Monday, August 14, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced the promotion of Tom Teisseyre, Ph.D. to chief operating officer. Dr. Teisseyre will oversee product design and development, clinical science, operations, cybersecurity, and technical service.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, is proud to be the first magnetic resonance imaging technology partner in an education-centric collaboration between the International Society for Magnetic Resonance in Medicine (ISMRM) and the Bill & Melinda Gates Foundation.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance imaging (MRI) system, today announced an expansion of clinical research to study the neurological effects of early childhood malnutrition in low and middle-income countries, with funding support from the Bill & Melinda Gates Foundation. The goal of the collaborative, multi-year global study is to address the impact of malnutrition on school readiness and academic achievement in the future development of children.

GUILFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, point-of-care MRI system, today announced first quarter 2023 financial results and provided a business update.

GUILFORD, Conn., April 20, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GUILFORD, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™ today announced fourth quarter and full year 2022 financial results and provided a business update.

GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the fourth quarter and full year 2022 on Tuesday, March 21, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Swoop® Portable MR Imaging® system positioned to offer even greater clinical utility in neurocritical care

CE Marking for the company’s portable MRI system with AI-powered imaging software demonstrates that the system complies with safety and performance requirements in the EU and provides the company optionality for future expansion beyond the current commercial focus

Latest Swoop® software improves image quality for DWI imaging of the brain

New study utilizes Hyperfine, Inc. portable MRI system in monitoring brain injury and evaluating physiological impacts

GUILFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that Brett Hale will join Hyperfine, Inc. on February 13, 2023 and will serve as Chief Administrative Officer & Chief Financial Officer (CFO). Alok Gupta, who currently serves as CFO, will step down on or about March 31 after a transition period.

Research highlights the significance and clinical relevance of portable MRI technology

GUILFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that the company will be participating in the upcoming 5th Annual Evercore ISI HealthCONx Conference.

GUILFORD, CONNECTICUT, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today reported financial results for the quarter ended September 30, 2022 and provided a business update. Management will host a corresponding conference call today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GUILFORD, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the third quarter 2022 on Thursday, November 10, 2022. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GUILFORD, Conn., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), (“Hyperfine” or “the Company”), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it has named medical device industry veteran Maria Sainz as President and Chief Executive Officer (CEO) of Hyperfine, effective October 24, 2022. Scott Huennekens, who currently serves as interim President and CEO, will stay on as Executive Chairperson of the Board.

Hyperfine, Inc. (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”) device, Swoop™, and Liminal Sciences, Inc. (“Liminal”), a medical device development company dedicated to non-invasive measurement of key vital signs in the brain, today announced their entry into a definitive business combination agreement with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ), (“HealthCor Catalio” or the “Company”), a special purpose acquisition company, or SPAC. Upon the closing of the business combination, HealthCor Catalio Acquisition Corp. will be renamed as Hyperfine, Inc., and the combined company’s Class A common stock is expected to be listed on The Nasdaq Stock Market (“Nasdaq”) under ticker symbol “HYPR.”

Hyperfine, Inc., creators of the world’s first portable magnetic resonance imaging device, has named Neela Paykel as General Counsel and Tom Teisseyre as Chief Product Officer, continuing its build-out of Hyperfine’s executive leadership team.